Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Autor: García Trevijano Cabetas M; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain macarena.garciatrevijano@salud.madrid.org., Escario-Gómez M; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain., González-Del Valle L; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain., Sobrino Jiménez C; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain., Bilbao Gomez-Martino C; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain., Romero-Garrido JA; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain., Benedi-González J; Pharmacy Department, Universidad Complutense de Madrid, Madrid, Comunidad de Madrid, Spain., Espinosa Arranz E; Medical Oncology Department, La Paz University Hospital, Madrid, Spain., Díaz Almirón M; Hospital Statistics Department, La Paz University Hospital, Madrid, Spain., Herrero Ambrosio A; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.

Publikováno v: European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2023 Sep; Vol. 30 (5), pp. 268-272. Date of Electronic Publication: 2021 Oct 07.